Meropenem Navamedic (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, leading to weakened cell walls and osmotic lysis of susceptible bacteria. Its structure confers stability against most β‑lactamases, giving it activity against a wide range of Gram‑positive, Gram‑negative, and anaerobic organisms.

The prescribed dose of Meropenem Navamedic is set by the treating clinician based on the type and severity of infection, the patient’s age, weight, and renal function. Dose adjustments are required for impaired kidney function, and the regimen may be modified for pediatric patients or those with specific comorbidities.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should assess each case individually and consider alternative agents when appropriate.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. The sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers enhanced stability against many β‑lactamases and a broader activity against Pseudomonas aeruginosa. Compared with non‑carbapenem agents, it provides more reliable coverage for multidrug‑resistant Gram‑negative infections, though cost and local susceptibility patterns influence selection.

Store Meropenem Navamedic below 25 °C in its original, sealed container. Protect the powder from moisture and direct light. Once reconstituted, the solution should be used promptly or stored according to the manufacturer’s instructions, typically at refrigerated temperatures and protected from light.

Meropenem Navamedic is supplied as a sterile powder for intravenous injection. It must be reconstituted with the appropriate diluent, then infused over a period recommended by the prescriber, usually 15–30 minutes. Administration is performed by qualified healthcare professionals in a clinical setting.

Serious adverse events include seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Prompt recognition and medical management are essential if these occur.

Meropenem Navamedic is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, as the drug may reduce valproate levels and precipitate seizures.